BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 26178471)

  • 1. D2HGDH regulates alpha-ketoglutarate levels and dioxygenase function by modulating IDH2.
    Lin AP; Abbas S; Kim SW; Ortega M; Bouamar H; Escobedo Y; Varadarajan P; Qin Y; Sudderth J; Schulz E; Deutsch A; Mohan S; Ulz P; Neumeister P; Rakheja D; Gao X; Hinck A; Weintraub ST; DeBerardinis RJ; Sill H; Dahia PL; Aguiar RC
    Nat Commun; 2015 Jul; 6():7768. PubMed ID: 26178471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
    Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
    Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screen for IDH1, IDH2, IDH3, D2HGDH and L2HGDH mutations in glioblastoma.
    Krell D; Assoku M; Galloway M; Mulholland P; Tomlinson I; Bardella C
    PLoS One; 2011; 6(5):e19868. PubMed ID: 21625441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 and IDH2 have critical roles in 2-hydroxyglutarate production in D-2-hydroxyglutarate dehydrogenase depleted cells.
    Matsunaga H; Futakuchi-Tsuchida A; Takahashi M; Ishikawa T; Tsuji M; Ando O
    Biochem Biophys Res Commun; 2012 Jul; 423(3):553-6. PubMed ID: 22683334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives.
    Yang H; Ye D; Guan KL; Xiong Y
    Clin Cancer Res; 2012 Oct; 18(20):5562-71. PubMed ID: 23071358
    [TBL] [Abstract][Full Text] [Related]  

  • 6. D-2-hydroxyglutarate dehydrogenase in breast carcinoma as a potent prognostic marker associated with proliferation.
    Hayashi C; Takagi K; Sato A; Yamaguchi M; Minemura H; Miki Y; Harada-Shoji N; Miyashita M; Sasano H; Suzuki T
    Histol Histopathol; 2021 Oct; 36(10):1053-1062. PubMed ID: 34296423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
    Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
    Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
    Ma S; Jiang B; Deng W; Gu ZK; Wu FZ; Li T; Xia Y; Yang H; Ye D; Xiong Y; Guan KL
    Oncotarget; 2015 Apr; 6(11):8606-20. PubMed ID: 25825982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
    Showalter MR; Hatakeyama J; Cajka T; VanderVorst K; Carraway KL; Fiehn O;
    Elife; 2017 Jun; 6():. PubMed ID: 28653623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct and opposite effects of leukemogenic
    Fortin J; Chiang MF; Meydan C; Foox J; Ramachandran P; Leca J; Lemonnier F; Li WY; Gams MS; Sakamoto T; Chu M; Tobin C; Laugesen E; Robinson TM; You-Ten A; Butler DJ; Berger T; Minden MD; Levine RL; Guidos CJ; Melnick AM; Mason CE; Mak TW
    Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2208176120. PubMed ID: 36652477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting isocitrate dehydrogenase (IDH) in cancer.
    Fujii T; Khawaja MR; DiNardo CD; Atkins JT; Janku F
    Discov Med; 2016 May; 21(117):373-80. PubMed ID: 27355333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
    Chang S; Yim S; Park H
    Exp Mol Med; 2019 Jun; 51(6):1-17. PubMed ID: 31221981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Computational approach to unravel the impact of missense mutations of proteins (D2HGDH and IDH2) causing D-2-hydroxyglutaric aciduria 2.
    Thirumal Kumar D; Jerushah Emerald L; George Priya Doss C; Sneha P; Siva R; Charles Emmanuel Jebaraj W; Zayed H
    Metab Brain Dis; 2018 Oct; 33(5):1699-1710. PubMed ID: 29987523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in isocitrate dehydrogenase 2 accelerate glioma cell migration via matrix metalloproteinase-2 and 9.
    Fu Y; Zheng Y; Li K; Huang R; Zheng S; An N; Liang A
    Biotechnol Lett; 2012 Mar; 34(3):441-6. PubMed ID: 22105553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. D-2-Hydroxyglutarate in Glioma Biology.
    Chou FJ; Liu Y; Lang F; Yang C
    Cells; 2021 Sep; 10(9):. PubMed ID: 34571995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MYC Regulation of D2HGDH and L2HGDH Influences the Epigenome and Epitranscriptome.
    Qiu Z; Lin AP; Jiang S; Elkashef SM; Myers J; Srikantan S; Sasi B; Cao JZ; Godley LA; Rakheja D; Lyu Y; Zheng S; Madesh M; Shiio Y; Dahia PLM; Aguiar RCT
    Cell Chem Biol; 2020 May; 27(5):538-550.e7. PubMed ID: 32101699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lithium chloride decreases proliferation and migration of C6 glioma cells harboring isocitrate dehydrogenase 2 mutant via GSK-3β.
    Fu Y; Zheng Y; Chan KG; Liang A; Hu F
    Mol Biol Rep; 2014 Jun; 41(6):3907-13. PubMed ID: 24549719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of α-ketoglutarate to citrate to support cell growth and viability.
    Wise DR; Ward PS; Shay JE; Cross JR; Gruber JJ; Sachdeva UM; Platt JM; DeMatteo RG; Simon MC; Thompson CB
    Proc Natl Acad Sci U S A; 2011 Dec; 108(49):19611-6. PubMed ID: 22106302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wild-type IDH2 is a therapeutic target for triple-negative breast cancer.
    Li JJ; Yu T; Zeng P; Tian J; Liu P; Qiao S; Wen S; Hu Y; Liu Q; Lu W; Zhang H; Huang P
    Nat Commun; 2024 Apr; 15(1):3445. PubMed ID: 38658533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH mutation impairs histone demethylation and results in a block to cell differentiation.
    Lu C; Ward PS; Kapoor GS; Rohle D; Turcan S; Abdel-Wahab O; Edwards CR; Khanin R; Figueroa ME; Melnick A; Wellen KE; O'Rourke DM; Berger SL; Chan TA; Levine RL; Mellinghoff IK; Thompson CB
    Nature; 2012 Feb; 483(7390):474-8. PubMed ID: 22343901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.